Trevi Therapeutics, Inc. (TRVI) News
Filter TRVI News Items
TRVI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TRVI News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TRVI News From Around the Web
Below are the latest news stories about TREVI THERAPEUTICS INC that investors may wish to consider to help them evaluate TRVI as an investment opportunity.
What Makes Trevi Therapeutics (TRVI) a New Buy StockTrevi Therapeutics (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare ConferenceTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced business updates ahead of its participation in the 14th Annual LifeSci Partners Corporate Access Event taking place in San Francisco, CA, from January 13-15, 2025. This event takes place during the week of t |
Trevi Therapeutics Announces Pricing of $50 Million Underwritten OfferingTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a price to investors of $4.00 per share, for total proceeds of $50 million, before deducting underwriting discounts and commissions and |
Trevi’s chronic cough trial in IPF subjects continues without sample size changeThe trial has enrolled 75% of its targeted participants. |
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?On Thursday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current sample size for the trial (N=160). The CORAL trial is a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) compared to placebo in IPF patients with |
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic CoughTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the positive outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in IPF patients with chronic cough, which requires no change to the current sample size for the tri |
Companies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral NalbuphineTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced positive results from the human abuse potential (HAP) study of oral nalbuphine. |
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, at 1:00p.m. ET. Held from December 3-5 in New Yo |
Q3 2024 Trevi Therapeutics Inc Earnings CallQ3 2024 Trevi Therapeutics Inc Earnings Call |